<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01817530</url>
  </required_header>
  <id_info>
    <org_study_id>M12-813</org_study_id>
    <secondary_id>2013-000082-37</secondary_id>
    <nct_id>NCT01817530</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)</brief_title>
  <official_title>A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety
      and efficacy of elagolix alone and in combination with add-back therapy versus placebo on
      heavy menstrual bleeding in premenopausal women 18 to 51 years of age with uterine fibroids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of &lt; 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month</measure>
    <time_frame>Baseline, Final Month (last 28 days of treatment)</time_frame>
    <description>The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL Volume of &lt; 80 mL at the Final Month and a ≥50% Reduction in MBL Volume from Baseline to the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a MBL Volume &lt; 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 56 to 29 Days of Treatment</measure>
    <time_frame>Baseline, second last 28 days of treatment (last 56 to 29 days of treatment)</time_frame>
    <description>The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL volume &lt; 80 mL and a ≥ 50% reduction in MBL volume from baseline during the last 56 to 29 days of last treatment. Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a MBL Volume &lt; 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 84 to 57 Days of Treatment</measure>
    <time_frame>Baseline, third last 28 days of treatment (last 84 to 57 days of treatment)</time_frame>
    <description>The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL volume &lt; 80 mL and a ≥ 50% reduction in MBL volume from baseline during the last 84 to 57 days of last treatment. Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved an MBL Volume of &lt; 80 mL at the Final Month</measure>
    <time_frame>Final Month (last 28 days of treatment)</time_frame>
    <description>Percentage of participants who achieved an MBL volume of &lt; 80 mL at the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month</measure>
    <time_frame>Baseline, Final Month (last 28 days of treatment)</time_frame>
    <description>Percentage of participants with a &gt;= 50% reduction from baseline in MBL to the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Amenorrhea During the Last 56 Days of Treatment</measure>
    <time_frame>Last 56 days of treatment (after 10 days from first dose date)</time_frame>
    <description>Amenorrhea is defined as having 0 days of bleeding or spotting based on observed validated and nonvalidated alkaline hematin data and having 0 days of bleeding or spotting, based on imputed electronic diary data during the last 56 days of treatment. Participants needed to have at least 66 days on treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Suppression of Bleeding During the Last 56 Days of Treatment</measure>
    <time_frame>Last 56 days of treatment (after 10 days from first dose date)</time_frame>
    <description>Suppression of bleeding is defined as having 0 days of bleeding based on observed validated and nonvalidated alkaline hematin data and having 0 days of bleeding (spotting is allowed) based on imputed electronic diary data during the last 56 days of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in the Number of Bleeding Days From Baseline to Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The number of days with any bleeding including spotting was calculated using data collected on daily bleeding diary. Baseline is defined as the last 28 days prior to the first dose day of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in the Number of Heavy Bleeding Days From Baseline to Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The number of days with heavy bleeding (either heavy or very heavy/gushing bleeding) was calculated using data collected on daily bleeding diary. Baseline is defined as the last 28 days prior to the first dose day of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bleeding Severity Scores From Baseline at the Final Month</measure>
    <time_frame>Baseline, Final Month (last 28 days of treatment)</time_frame>
    <description>The average bleeding score was calculated for each 28-day interval starting on Day 29 using data collected on daily bleeding diary using the Mansfield-Voda-Jorgenson (MVJ) Menstrual Bleeding Scale (1=spotting, 2 = very light bleeding, 3 = light bleeding, 4 = moderate bleeding, 5 = heavy bleeding, 6 = very heavy/gushing bleeding). Baseline is defined as the last 28 days prior to the first day of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Hemoglobin Concentration From Baseline to Final Visit</measure>
    <time_frame>Baseline, Final Visit during treatment period (Month 6 or early termination)</time_frame>
    <description>Baseline is defined as the last measurement prior to the first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Change From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit</measure>
    <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
    <description>Volume of the total fibroid volume (3 largest fibroids), as measured by transvaginal ultrasound, or transabdominal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Change From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit</measure>
    <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
    <description>Volume of the largest fibroid (primary fibroid), as measured by transvaginal ultrasound, or transabdominal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percentage Change From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit</measure>
    <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
    <description>Uterine volume, as measured by transvaginal ultrasound or transabdominal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥ 25% Reduction From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit</measure>
    <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
    <description>Total fibroid volume (3 largest fibroids) was measured by transvaginal ultrasound, or transabdominal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥ 25% Reduction From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit</measure>
    <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
    <description>Volume of the largest fibroid (primary fibroid) was measured by transvaginal ultrasound or transabdominal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With ≥ 25% Reduction From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit</measure>
    <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
    <description>Uterine volume was measured by transvaginal ultrasound or transabdominal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Month in Non-Bleeding Uterine Fibroids Symptom (NBUFSQ) Questionnaire</measure>
    <time_frame>Baseline, Days 1-28, Days 29-56, Days 57-84, Days 85-112, Days 113-140, Days 141-168, Final Month of treatment, Post-treatment (PT) Days 1-28, PT Days 29-56, PT Days 57-84, PT Days 85-112, PT Days 113-140, PT Days 141-168</time_frame>
    <description>The NBUFSQ (8 items) is a brief patient-reported daily diary that assesses non-bleeding symptoms experienced by women with uterine fibroids. It includes 6 items, asking women to rate their symptoms (abdominal/pelvic pain, pressure, and cramping, back pain, bloating, and urinary problems) in the past 24 hours using an 11-point numeric response scale that ranges from 0 (i.e., no symptom) to 10 (i.e., worst possible symptom) and 2 items to address urinary frequency during the daytime and at night. Data presented in the sum of scores to the 6 symptom questions, ranging from 0 (no symptoms) to 60 (worst possible symptoms). Baseline is defined as the last 28 days prior to the first day of study drug. Final Month is defined as the last 28 days prior to and including the last dose date of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Successfully Avoided Surgical or Invasive Procedures for Uterine Fibroids</measure>
    <time_frame>Month 6</time_frame>
    <description>The percentage of participants who successfully avoided surgical or invasive procedures for Uterine Fibroids was assessed.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">571</enrollment>
  <condition>Heavy Uterine Bleeding</condition>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for elagolix and placebo for E2/NETA twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Elagolix 300 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix 300 mg BID alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Elagolix 300 mg BID plus LD E2/NETA QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix 300 mg BID plus low-dose (LD) E2/NETA once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Elagolix 300 mg BID plus SD E2/NETA QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix 300 mg BID plus standard-dose (SD) E2/NETA QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for elagolix and E2/NETA QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Elagolix 600 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix 600 mg QD alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Elagolix 600 mg QD plus LD E2/NETA QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Elagolix 600 mg QD plus SD E2/NETA QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Elagolix placebo</intervention_name>
    <description>oral coated tablet</description>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix</intervention_name>
    <description>oral coated tablet</description>
    <arm_group_label>Cohort 1: Elagolix 300 mg BID</arm_group_label>
    <arm_group_label>Cohort 1: Elagolix 300 mg BID plus LD E2/NETA QD</arm_group_label>
    <arm_group_label>Cohort 1: Elagolix 300 mg BID plus SD E2/NETA QD</arm_group_label>
    <arm_group_label>Cohort 2: Elagolix 600 mg QD</arm_group_label>
    <arm_group_label>Cohort 2: Elagolix 600 mg QD plus LD E2/NETA QD</arm_group_label>
    <arm_group_label>Cohort 2: Elagolix 600 mg QD plus SD E2/NETA QD</arm_group_label>
    <other_name>ABT-620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5 mg estradiol / 0.1 mg norethindrone acetate</intervention_name>
    <description>oral hard capsule</description>
    <arm_group_label>Cohort 1: Elagolix 300 mg BID plus LD E2/NETA QD</arm_group_label>
    <arm_group_label>Cohort 2: Elagolix 600 mg QD plus LD E2/NETA QD</arm_group_label>
    <other_name>Activelle, Activella, low dose (LD) E2/NETA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 mg estradiol / 0.5 mg norethindrone acetate</intervention_name>
    <description>oral hard capsule</description>
    <arm_group_label>Cohort 1: Elagolix 300 mg BID plus SD E2/NETA QD</arm_group_label>
    <arm_group_label>Cohort 2: Elagolix 600 mg QD plus SD E2/NETA QD</arm_group_label>
    <other_name>Activelle</other_name>
    <other_name>Activella</other_name>
    <other_name>standard dose (SD) E2/NETA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2/NETA placebo</intervention_name>
    <description>oral hard capsule</description>
    <arm_group_label>Cohort 1: Elagolix 300 mg BID</arm_group_label>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_label>Cohort 2: Elagolix 600 mg QD</arm_group_label>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is pre-menopausal female 18 to 51 years of age at Screening.

          -  Subject has diagnosis of uterine fibroids documented by a Pelvic Ultrasound.

          -  Subject has heavy uterine bleeding associated with uterine fibroids.

        Exclusion Criteria:

          -  Subject has had a myomectomy, uterine artery embolization or high intensity focused
             ultrasound for fibroid destruction within 6 months prior to Screening or endometrial
             ablation within 5 years prior to Screening.

          -  Subject has a history of osteoporosis or other metabolic bone disease.

          -  Subject shows evidence of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including
             depression, schizophrenia, bipolar disorder), or neurologic diseases or any
             uncontrolled medical illness such as uncontrolled type 2 diabetes. Subject has any
             history of attempted suicide.

          -  Subject has a history of clinically significant condition(s) including but not limited
             to: * Symptomatic Endometriosis * Epilepsy or seizures * Type 1 diabetes * Chronic
             kidney disease * Any cancer (except treated basal cell carcinoma of the skin),
             including breast or ovarian cancer or subject has taken any systemic cancer
             chemotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>51 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Owens, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2013</study_first_posted>
  <results_first_submitted>June 9, 2020</results_first_submitted>
  <results_first_submitted_qc>July 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2020</results_first_posted>
  <disposition_first_submitted>June 15, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 15, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 16, 2016</disposition_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Fibroids</keyword>
  <keyword>Leiomyomata</keyword>
  <keyword>Elagolix</keyword>
  <keyword>Menorrhagia</keyword>
  <keyword>Elagolix sodium</keyword>
  <keyword>Heavy Uterine Bleeding</keyword>
  <keyword>ABT-620</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone Acetate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall, 571 female participants were enrolled into the study across 86 sites (5 sites in the UK, 4 in Chile, 2 in Canada, 4 in Puerto Rico, and 71 in the US).</recruitment_details>
      <pre_assignment_details>Four participants were randomized in error; they were not dosed and were excluded from all analyses including demographic summaries.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Placebo</title>
          <description>Placebo for elagolix twice daily (BID) and placebo for E2/NETA once daily (QD)</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: Elagolix 300 mg BID</title>
          <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
          <description>Elagolix 300 mg BID plus low-dose (LD) E2/NETA QD</description>
        </group>
        <group group_id="P4">
          <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
          <description>Elagolix 300 mg BID plus standard-dose (SD) E2/NETA QD</description>
        </group>
        <group group_id="P5">
          <title>Cohort 2: Placebo</title>
          <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
        </group>
        <group group_id="P6">
          <title>Cohort 2: Elagolix 600 mg QD</title>
          <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
        </group>
        <group group_id="P7">
          <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
          <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
        </group>
        <group group_id="P8">
          <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
          <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="78"/>
                <participants group_id="P6" count="77"/>
                <participants group_id="P7" count="76"/>
                <participants group_id="P8" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="67"/>
                <participants group_id="P6" count="58"/>
                <participants group_id="P7" count="53"/>
                <participants group_id="P8" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Exclusionary Medication Received</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Noncompliant</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery or Invasive Intervention</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Placebo</title>
          <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1: Elagolix 300 mg BID</title>
          <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
          <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
        </group>
        <group group_id="B4">
          <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
          <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
        </group>
        <group group_id="B5">
          <title>Cohort 2: Placebo</title>
          <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
        </group>
        <group group_id="B6">
          <title>Cohort 2: Elagolix 600 mg QD</title>
          <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
        </group>
        <group group_id="B7">
          <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
          <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
        </group>
        <group group_id="B8">
          <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
          <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="64"/>
            <count group_id="B4" value="65"/>
            <count group_id="B5" value="78"/>
            <count group_id="B6" value="77"/>
            <count group_id="B7" value="76"/>
            <count group_id="B8" value="77"/>
            <count group_id="B9" value="567"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.5" spread="6.14"/>
                    <measurement group_id="B2" value="42.0" spread="4.76"/>
                    <measurement group_id="B3" value="43.0" spread="5.02"/>
                    <measurement group_id="B4" value="43.8" spread="4.66"/>
                    <measurement group_id="B5" value="42.3" spread="4.78"/>
                    <measurement group_id="B6" value="42.1" spread="4.93"/>
                    <measurement group_id="B7" value="41.1" spread="5.74"/>
                    <measurement group_id="B8" value="42.2" spread="5.40"/>
                    <measurement group_id="B9" value="42.3" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="78"/>
                    <measurement group_id="B6" value="77"/>
                    <measurement group_id="B7" value="76"/>
                    <measurement group_id="B8" value="77"/>
                    <measurement group_id="B9" value="567"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of &lt; 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month</title>
        <description>The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL Volume of &lt; 80 mL at the Final Month and a ≥50% Reduction in MBL Volume from Baseline to the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
        <time_frame>Baseline, Final Month (last 28 days of treatment)</time_frame>
        <population>Modified Intent-to-Treat (ITT): randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 28 days of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of &lt; 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month</title>
          <description>The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL Volume of &lt; 80 mL at the Final Month and a ≥50% Reduction in MBL Volume from Baseline to the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
          <population>Modified Intent-to-Treat (ITT): randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 28 days of treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="71"/>
                <count group_id="O7" value="73"/>
                <count group_id="O8" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.56"/>
                    <measurement group_id="O2" value="91.94"/>
                    <measurement group_id="O3" value="85.25"/>
                    <measurement group_id="O4" value="79.03"/>
                    <measurement group_id="O5" value="31.58"/>
                    <measurement group_id="O6" value="90.14"/>
                    <measurement group_id="O7" value="72.6"/>
                    <measurement group_id="O8" value="81.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>32.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.12</ci_lower_limit>
            <ci_upper_limit>95.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>16.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.72</ci_lower_limit>
            <ci_upper_limit>41.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.79</ci_lower_limit>
            <ci_upper_limit>25.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>19.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.81</ci_lower_limit>
            <ci_upper_limit>49.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.95</ci_lower_limit>
            <ci_upper_limit>12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>10.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.79</ci_lower_limit>
            <ci_upper_limit>22.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a MBL Volume &lt; 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 56 to 29 Days of Treatment</title>
        <description>The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL volume &lt; 80 mL and a ≥ 50% reduction in MBL volume from baseline during the last 56 to 29 days of last treatment. Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
        <time_frame>Baseline, second last 28 days of treatment (last 56 to 29 days of treatment)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 56 days of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a MBL Volume &lt; 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 56 to 29 Days of Treatment</title>
          <description>The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL volume &lt; 80 mL and a ≥ 50% reduction in MBL volume from baseline during the last 56 to 29 days of last treatment. Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 56 days of treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="68"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.29"/>
                    <measurement group_id="O2" value="94.83"/>
                    <measurement group_id="O3" value="88.14"/>
                    <measurement group_id="O4" value="85.00"/>
                    <measurement group_id="O5" value="18.42"/>
                    <measurement group_id="O6" value="85.29"/>
                    <measurement group_id="O7" value="67.19"/>
                    <measurement group_id="O8" value="77.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>156.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>38.04</ci_lower_limit>
            <ci_upper_limit>641.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>66.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.1</ci_lower_limit>
            <ci_upper_limit>206.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>52.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.42</ci_lower_limit>
            <ci_upper_limit>156.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>25.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.45</ci_lower_limit>
            <ci_upper_limit>61.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.38</ci_lower_limit>
            <ci_upper_limit>21.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>16.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.13</ci_lower_limit>
            <ci_upper_limit>36.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a MBL Volume &lt; 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 84 to 57 Days of Treatment</title>
        <description>The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL volume &lt; 80 mL and a ≥ 50% reduction in MBL volume from baseline during the last 84 to 57 days of last treatment. Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
        <time_frame>Baseline, third last 28 days of treatment (last 84 to 57 days of treatment)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 84 days of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a MBL Volume &lt; 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 84 to 57 Days of Treatment</title>
          <description>The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL volume &lt; 80 mL and a ≥ 50% reduction in MBL volume from baseline during the last 84 to 57 days of last treatment. Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 84 days of treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="58"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="66"/>
                <count group_id="O7" value="62"/>
                <count group_id="O8" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.67"/>
                    <measurement group_id="O2" value="96.43"/>
                    <measurement group_id="O3" value="89.47"/>
                    <measurement group_id="O4" value="79.31"/>
                    <measurement group_id="O5" value="21.62"/>
                    <measurement group_id="O6" value="86.36"/>
                    <measurement group_id="O7" value="74.19"/>
                    <measurement group_id="O8" value="72.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>123.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.93</ci_lower_limit>
            <ci_upper_limit>584.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>40.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.59</ci_lower_limit>
            <ci_upper_limit>121.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>19.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.44</ci_lower_limit>
            <ci_upper_limit>48.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>22.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.29</ci_lower_limit>
            <ci_upper_limit>55.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>10.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.88</ci_lower_limit>
            <ci_upper_limit>24.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.46</ci_lower_limit>
            <ci_upper_limit>21.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved an MBL Volume of &lt; 80 mL at the Final Month</title>
        <description>Percentage of participants who achieved an MBL volume of &lt; 80 mL at the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
        <time_frame>Final Month (last 28 days of treatment)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 28 days of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved an MBL Volume of &lt; 80 mL at the Final Month</title>
          <description>Percentage of participants who achieved an MBL volume of &lt; 80 mL at the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 28 days of treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="71"/>
                <count group_id="O7" value="73"/>
                <count group_id="O8" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.81"/>
                    <measurement group_id="O2" value="91.94"/>
                    <measurement group_id="O3" value="88.52"/>
                    <measurement group_id="O4" value="79.03"/>
                    <measurement group_id="O5" value="36.84"/>
                    <measurement group_id="O6" value="91.55"/>
                    <measurement group_id="O7" value="72.6"/>
                    <measurement group_id="O8" value="85.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>24.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.57</ci_lower_limit>
            <ci_upper_limit>71.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>17.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.57</ci_lower_limit>
            <ci_upper_limit>45.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.79</ci_lower_limit>
            <ci_upper_limit>19.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>18.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.11</ci_lower_limit>
            <ci_upper_limit>49.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.43</ci_lower_limit>
            <ci_upper_limit>10.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>P value is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.17</ci_lower_limit>
            <ci_upper_limit>26.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month</title>
        <description>Percentage of participants with a &gt;= 50% reduction from baseline in MBL to the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
        <time_frame>Baseline, Final Month (last 28 days of treatment)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 28 days of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month</title>
          <description>Percentage of participants with a &gt;= 50% reduction from baseline in MBL to the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 28 days of treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="62"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="71"/>
                <count group_id="O7" value="73"/>
                <count group_id="O8" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.25"/>
                    <measurement group_id="O2" value="93.55"/>
                    <measurement group_id="O3" value="86.89"/>
                    <measurement group_id="O4" value="82.26"/>
                    <measurement group_id="O5" value="35.53"/>
                    <measurement group_id="O6" value="90.14"/>
                    <measurement group_id="O7" value="79.45"/>
                    <measurement group_id="O8" value="85.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>31.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.02</ci_lower_limit>
            <ci_upper_limit>98.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>14.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.77</ci_lower_limit>
            <ci_upper_limit>35.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.23</ci_lower_limit>
            <ci_upper_limit>22.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>16.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.66</ci_lower_limit>
            <ci_upper_limit>41.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.36</ci_lower_limit>
            <ci_upper_limit>14.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>10.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.85</ci_lower_limit>
            <ci_upper_limit>23.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a chi-square test.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Amenorrhea During the Last 56 Days of Treatment</title>
        <description>Amenorrhea is defined as having 0 days of bleeding or spotting based on observed validated and nonvalidated alkaline hematin data and having 0 days of bleeding or spotting, based on imputed electronic diary data during the last 56 days of treatment. Participants needed to have at least 66 days on treatment.</description>
        <time_frame>Last 56 days of treatment (after 10 days from first dose date)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 66 days of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Amenorrhea During the Last 56 Days of Treatment</title>
          <description>Amenorrhea is defined as having 0 days of bleeding or spotting based on observed validated and nonvalidated alkaline hematin data and having 0 days of bleeding or spotting, based on imputed electronic diary data during the last 56 days of treatment. Participants needed to have at least 66 days on treatment.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 66 days of treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="67"/>
                <count group_id="O7" value="63"/>
                <count group_id="O8" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="56.1"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="28.3"/>
                    <measurement group_id="O5" value="1.3"/>
                    <measurement group_id="O6" value="50.7"/>
                    <measurement group_id="O7" value="17.5"/>
                    <measurement group_id="O8" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Suppression of Bleeding During the Last 56 Days of Treatment</title>
        <description>Suppression of bleeding is defined as having 0 days of bleeding based on observed validated and nonvalidated alkaline hematin data and having 0 days of bleeding (spotting is allowed) based on imputed electronic diary data during the last 56 days of treatment.</description>
        <time_frame>Last 56 days of treatment (after 10 days from first dose date)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 66 days of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Suppression of Bleeding During the Last 56 Days of Treatment</title>
          <description>Suppression of bleeding is defined as having 0 days of bleeding based on observed validated and nonvalidated alkaline hematin data and having 0 days of bleeding (spotting is allowed) based on imputed electronic diary data during the last 56 days of treatment.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Excludes participants with &lt; 66 days of treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="57"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="75"/>
                <count group_id="O6" value="67"/>
                <count group_id="O7" value="63"/>
                <count group_id="O8" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="75.4"/>
                    <measurement group_id="O3" value="52.6"/>
                    <measurement group_id="O4" value="43.3"/>
                    <measurement group_id="O5" value="2.7"/>
                    <measurement group_id="O6" value="67.2"/>
                    <measurement group_id="O7" value="31.7"/>
                    <measurement group_id="O8" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in the Number of Bleeding Days From Baseline to Month 6</title>
        <description>The number of days with any bleeding including spotting was calculated using data collected on daily bleeding diary. Baseline is defined as the last 28 days prior to the first dose day of study drug.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in the Number of Bleeding Days From Baseline to Month 6</title>
          <description>The number of days with any bleeding including spotting was calculated using data collected on daily bleeding diary. Baseline is defined as the last 28 days prior to the first dose day of study drug.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and Month 6.</population>
          <units>days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.63"/>
                    <measurement group_id="O2" value="-4.9" spread="1.15"/>
                    <measurement group_id="O3" value="-2.7" spread="0.75"/>
                    <measurement group_id="O4" value="-1.1" spread="0.69"/>
                    <measurement group_id="O5" value="-1.4" spread="0.49"/>
                    <measurement group_id="O6" value="-3.3" spread="0.87"/>
                    <measurement group_id="O7" value="-1.3" spread="0.66"/>
                    <measurement group_id="O8" value="-1.8" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-3.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.28</ci_lower_limit>
            <ci_upper_limit>-1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.132</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.44</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.876</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.71</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.055</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.92</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.898</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.52</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.59</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.05</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in the Number of Heavy Bleeding Days From Baseline to Month 6</title>
        <description>The number of days with heavy bleeding (either heavy or very heavy/gushing bleeding) was calculated using data collected on daily bleeding diary. Baseline is defined as the last 28 days prior to the first dose day of study drug.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and Month 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in the Number of Heavy Bleeding Days From Baseline to Month 6</title>
          <description>The number of days with heavy bleeding (either heavy or very heavy/gushing bleeding) was calculated using data collected on daily bleeding diary. Baseline is defined as the last 28 days prior to the first dose day of study drug.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and Month 6.</population>
          <units>days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="26"/>
                <count group_id="O8" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.15"/>
                    <measurement group_id="O2" value="-2.0" spread="0.27"/>
                    <measurement group_id="O3" value="-1.9" spread="0.18"/>
                    <measurement group_id="O4" value="-1.7" spread="0.16"/>
                    <measurement group_id="O5" value="-0.7" spread="0.14"/>
                    <measurement group_id="O6" value="-1.2" spread="0.25"/>
                    <measurement group_id="O7" value="-1.4" spread="0.19"/>
                    <measurement group_id="O8" value="-1.8" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-1.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.64</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-1.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.42</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.118</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-1.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.51</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bleeding Severity Scores From Baseline at the Final Month</title>
        <description>The average bleeding score was calculated for each 28-day interval starting on Day 29 using data collected on daily bleeding diary using the Mansfield-Voda-Jorgenson (MVJ) Menstrual Bleeding Scale (1=spotting, 2 = very light bleeding, 3 = light bleeding, 4 = moderate bleeding, 5 = heavy bleeding, 6 = very heavy/gushing bleeding). Baseline is defined as the last 28 days prior to the first day of study drug.</description>
        <time_frame>Baseline, Final Month (last 28 days of treatment)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and final month.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bleeding Severity Scores From Baseline at the Final Month</title>
          <description>The average bleeding score was calculated for each 28-day interval starting on Day 29 using data collected on daily bleeding diary using the Mansfield-Voda-Jorgenson (MVJ) Menstrual Bleeding Scale (1=spotting, 2 = very light bleeding, 3 = light bleeding, 4 = moderate bleeding, 5 = heavy bleeding, 6 = very heavy/gushing bleeding). Baseline is defined as the last 28 days prior to the first day of study drug.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and final month.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="48"/>
                <count group_id="O8" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.08"/>
                    <measurement group_id="O2" value="-0.7" spread="0.14"/>
                    <measurement group_id="O3" value="-0.4" spread="0.10"/>
                    <measurement group_id="O4" value="-0.1" spread="0.10"/>
                    <measurement group_id="O5" value="-0.2" spread="0.08"/>
                    <measurement group_id="O6" value="-0.4" spread="0.14"/>
                    <measurement group_id="O7" value="-0.3" spread="0.10"/>
                    <measurement group_id="O8" value="-0.1" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from an ANCOVA model with treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.314</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from an ANCOVA model with treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.307</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from an ANCOVA model with treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.106</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from an ANCOVA model with treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.424</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from an ANCOVA model with treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.528</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from an ANCOVA model with treatment as the main effect and baseline as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS mean change</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Hemoglobin Concentration From Baseline to Final Visit</title>
        <description>Baseline is defined as the last measurement prior to the first dose of study drug.</description>
        <time_frame>Baseline, Final Visit during treatment period (Month 6 or early termination)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and final month.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Hemoglobin Concentration From Baseline to Final Visit</title>
          <description>Baseline is defined as the last measurement prior to the first dose of study drug.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and final month.</population>
          <units>g/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="71"/>
                <count group_id="O7" value="72"/>
                <count group_id="O8" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.17"/>
                    <measurement group_id="O2" value="1.9" spread="0.17"/>
                    <measurement group_id="O3" value="1.9" spread="0.17"/>
                    <measurement group_id="O4" value="1.4" spread="0.17"/>
                    <measurement group_id="O5" value="0.3" spread="0.15"/>
                    <measurement group_id="O6" value="1.4" spread="0.16"/>
                    <measurement group_id="O7" value="1.1" spread="0.16"/>
                    <measurement group_id="O8" value="1.2" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each postbaseline time point is from an ANCOVA model with treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage Change From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit</title>
        <description>Volume of the total fibroid volume (3 largest fibroids), as measured by transvaginal ultrasound, or transabdominal ultrasound.</description>
        <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and final month.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit</title>
          <description>Volume of the total fibroid volume (3 largest fibroids), as measured by transvaginal ultrasound, or transabdominal ultrasound.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and final month.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="77"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="57"/>
                    <count group_id="O7" value="53"/>
                    <count group_id="O8" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="33.61"/>
                    <measurement group_id="O2" value="-41.9" spread="24.87"/>
                    <measurement group_id="O3" value="-24.6" spread="27.58"/>
                    <measurement group_id="O4" value="-9.8" spread="40.31"/>
                    <measurement group_id="O5" value="5.4" spread="27.18"/>
                    <measurement group_id="O6" value="-34.4" spread="25.56"/>
                    <measurement group_id="O7" value="-17.5" spread="27.76"/>
                    <measurement group_id="O8" value="-4.6" spread="39.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="50.97"/>
                    <measurement group_id="O2" value="-40.2" spread="27.6"/>
                    <measurement group_id="O3" value="-23.3" spread="30.34"/>
                    <measurement group_id="O4" value="-8.8" spread="47.81"/>
                    <measurement group_id="O5" value="-1.8" spread="30.1"/>
                    <measurement group_id="O6" value="-34.2" spread="31.14"/>
                    <measurement group_id="O7" value="-17.8" spread="30.49"/>
                    <measurement group_id="O8" value="-1.1" spread="46.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="66"/>
                    <count group_id="O6" value="59"/>
                    <count group_id="O7" value="55"/>
                    <count group_id="O8" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="48.59"/>
                    <measurement group_id="O2" value="-39.6" spread="28.66"/>
                    <measurement group_id="O3" value="-24.0" spread="29.93"/>
                    <measurement group_id="O4" value="-12.9" spread="46.2"/>
                    <measurement group_id="O5" value="0.1" spread="28.82"/>
                    <measurement group_id="O6" value="-36.4" spread="30.07"/>
                    <measurement group_id="O7" value="-16.6" spread="32.65"/>
                    <measurement group_id="O8" value="-1.6" spread="42.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.032</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.495</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.329</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage Change From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit</title>
        <description>Volume of the largest fibroid (primary fibroid), as measured by transvaginal ultrasound, or transabdominal ultrasound.</description>
        <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit</title>
          <description>Volume of the largest fibroid (primary fibroid), as measured by transvaginal ultrasound, or transabdominal ultrasound.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="77"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="57"/>
                    <count group_id="O7" value="53"/>
                    <count group_id="O8" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="35.31"/>
                    <measurement group_id="O2" value="-35.5" spread="26.32"/>
                    <measurement group_id="O3" value="-20.3" spread="33.54"/>
                    <measurement group_id="O4" value="-3.7" spread="39.13"/>
                    <measurement group_id="O5" value="6.7" spread="27.66"/>
                    <measurement group_id="O6" value="-33.6" spread="23.74"/>
                    <measurement group_id="O7" value="-17.2" spread="27.39"/>
                    <measurement group_id="O8" value="-1.9" spread="39.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="48.65"/>
                    <measurement group_id="O2" value="-36.1" spread="30.59"/>
                    <measurement group_id="O3" value="-19.6" spread="32.1"/>
                    <measurement group_id="O4" value="0.0" spread="47.07"/>
                    <measurement group_id="O5" value="1.4" spread="30.03"/>
                    <measurement group_id="O6" value="-33.5" spread="31.89"/>
                    <measurement group_id="O7" value="-12.2" spread="40.59"/>
                    <measurement group_id="O8" value="-0.7" spread="42.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="66"/>
                    <count group_id="O6" value="59"/>
                    <count group_id="O7" value="55"/>
                    <count group_id="O8" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="46.63"/>
                    <measurement group_id="O2" value="-35.6" spread="30.81"/>
                    <measurement group_id="O3" value="20.0" spread="31.73"/>
                    <measurement group_id="O4" value="-2.7" spread="46.63"/>
                    <measurement group_id="O5" value="3.0" spread="28.7"/>
                    <measurement group_id="O6" value="-34.8" spread="30.36"/>
                    <measurement group_id="O7" value="-12.8" spread="39.65"/>
                    <measurement group_id="O8" value="0.0" spread="40.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.040</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.098</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.409</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.094</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.393</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percentage Change From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit</title>
        <description>Uterine volume, as measured by transvaginal ultrasound or transabdominal ultrasound.</description>
        <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit</title>
          <description>Uterine volume, as measured by transvaginal ultrasound or transabdominal ultrasound.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="77"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="72"/>
                    <count group_id="O6" value="63"/>
                    <count group_id="O7" value="57"/>
                    <count group_id="O8" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="25.12"/>
                    <measurement group_id="O2" value="-30.9" spread="28.87"/>
                    <measurement group_id="O3" value="-19.4" spread="22.48"/>
                    <measurement group_id="O4" value="-7.3" spread="20.7"/>
                    <measurement group_id="O5" value="8.4" spread="24.26"/>
                    <measurement group_id="O6" value="-24.7" spread="21.98"/>
                    <measurement group_id="O7" value="-15.7" spread="21.84"/>
                    <measurement group_id="O8" value="-6.1" spread="18.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="56"/>
                    <count group_id="O7" value="49"/>
                    <count group_id="O8" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="40.25"/>
                    <measurement group_id="O2" value="-35.6" spread="25.74"/>
                    <measurement group_id="O3" value="-21.9" spread="27.64"/>
                    <measurement group_id="O4" value="-13.2" spread="23.86"/>
                    <measurement group_id="O5" value="10.7" spread="20.73"/>
                    <measurement group_id="O6" value="-26.00" spread="29.51"/>
                    <measurement group_id="O7" value="-13.5" spread="25.09"/>
                    <measurement group_id="O8" value="-9.0" spread="22.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="72"/>
                    <count group_id="O6" value="65"/>
                    <count group_id="O7" value="58"/>
                    <count group_id="O8" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="38.06"/>
                    <measurement group_id="O2" value="-31.5" spread="31.44"/>
                    <measurement group_id="O3" value="-22.0" spread="28.52"/>
                    <measurement group_id="O4" value="-11.8" spread="22.56"/>
                    <measurement group_id="O5" value="11.6" spread="25.38"/>
                    <measurement group_id="O6" value="-26.6" spread="28.26"/>
                    <measurement group_id="O7" value="-11.5" spread="25.33"/>
                    <measurement group_id="O8" value="-6.7" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from Kruskal-Wallis analysis with treatment as the main effect.</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥ 25% Reduction From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit</title>
        <description>Total fibroid volume (3 largest fibroids) was measured by transvaginal ultrasound, or transabdominal ultrasound.</description>
        <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 25% Reduction From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit</title>
          <description>Total fibroid volume (3 largest fibroids) was measured by transvaginal ultrasound, or transabdominal ultrasound.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="77"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="57"/>
                    <count group_id="O7" value="53"/>
                    <count group_id="O8" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="79.6"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="31.9"/>
                    <measurement group_id="O5" value="9.4"/>
                    <measurement group_id="O6" value="66.7"/>
                    <measurement group_id="O7" value="34.0"/>
                    <measurement group_id="O8" value="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="54.2"/>
                    <measurement group_id="O4" value="40.5"/>
                    <measurement group_id="O5" value="18.2"/>
                    <measurement group_id="O6" value="62.0"/>
                    <measurement group_id="O7" value="40.9"/>
                    <measurement group_id="O8" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="66"/>
                    <count group_id="O6" value="59"/>
                    <count group_id="O7" value="55"/>
                    <count group_id="O8" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5"/>
                    <measurement group_id="O2" value="73.6"/>
                    <measurement group_id="O3" value="57.4"/>
                    <measurement group_id="O4" value="41.2"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="64.4"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.061</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.085</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.049</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.088</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥ 25% Reduction From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit</title>
        <description>Volume of the largest fibroid (primary fibroid) was measured by transvaginal ultrasound or transabdominal ultrasound.</description>
        <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 25% Reduction From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit</title>
          <description>Volume of the largest fibroid (primary fibroid) was measured by transvaginal ultrasound or transabdominal ultrasound.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="77"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="57"/>
                    <count group_id="O7" value="53"/>
                    <count group_id="O8" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="67.3"/>
                    <measurement group_id="O3" value="46.2"/>
                    <measurement group_id="O4" value="23.4"/>
                    <measurement group_id="O5" value="10.9"/>
                    <measurement group_id="O6" value="63.2"/>
                    <measurement group_id="O7" value="37.7"/>
                    <measurement group_id="O8" value="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="44"/>
                    <count group_id="O8" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="70.5"/>
                    <measurement group_id="O3" value="47.9"/>
                    <measurement group_id="O4" value="26.2"/>
                    <measurement group_id="O5" value="14.5"/>
                    <measurement group_id="O6" value="64.0"/>
                    <measurement group_id="O7" value="38.6"/>
                    <measurement group_id="O8" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="66"/>
                    <count group_id="O6" value="59"/>
                    <count group_id="O7" value="55"/>
                    <count group_id="O8" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5"/>
                    <measurement group_id="O2" value="69.8"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="27.5"/>
                    <measurement group_id="O5" value="13.6"/>
                    <measurement group_id="O6" value="66.1"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.188</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.104</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.859</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.722</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.032</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With ≥ 25% Reduction From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit</title>
        <description>Uterine volume was measured by transvaginal ultrasound or transabdominal ultrasound.</description>
        <time_frame>Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥ 25% Reduction From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit</title>
          <description>Uterine volume was measured by transvaginal ultrasound or transabdominal ultrasound.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="77"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="72"/>
                    <count group_id="O6" value="63"/>
                    <count group_id="O7" value="57"/>
                    <count group_id="O8" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="73.1"/>
                    <measurement group_id="O3" value="42.9"/>
                    <measurement group_id="O4" value="18.5"/>
                    <measurement group_id="O5" value="1.4"/>
                    <measurement group_id="O6" value="57.1"/>
                    <measurement group_id="O7" value="36.8"/>
                    <measurement group_id="O8" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="47"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="56"/>
                    <count group_id="O7" value="49"/>
                    <count group_id="O8" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="78.7"/>
                    <measurement group_id="O3" value="58.0"/>
                    <measurement group_id="O4" value="31.9"/>
                    <measurement group_id="O5" value="1.6"/>
                    <measurement group_id="O6" value="62.5"/>
                    <measurement group_id="O7" value="32.7"/>
                    <measurement group_id="O8" value="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="56"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="72"/>
                    <count group_id="O6" value="65"/>
                    <count group_id="O7" value="58"/>
                    <count group_id="O8" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="73.2"/>
                    <measurement group_id="O3" value="58.9"/>
                    <measurement group_id="O4" value="26.8"/>
                    <measurement group_id="O5" value="1.4"/>
                    <measurement group_id="O6" value="63.1"/>
                    <measurement group_id="O7" value="29.3"/>
                    <measurement group_id="O8" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Month 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Final Visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo is from a logistic regression model including treatment as the main effect and baseline value as a covariate.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Month in Non-Bleeding Uterine Fibroids Symptom (NBUFSQ) Questionnaire</title>
        <description>The NBUFSQ (8 items) is a brief patient-reported daily diary that assesses non-bleeding symptoms experienced by women with uterine fibroids. It includes 6 items, asking women to rate their symptoms (abdominal/pelvic pain, pressure, and cramping, back pain, bloating, and urinary problems) in the past 24 hours using an 11-point numeric response scale that ranges from 0 (i.e., no symptom) to 10 (i.e., worst possible symptom) and 2 items to address urinary frequency during the daytime and at night. Data presented in the sum of scores to the 6 symptom questions, ranging from 0 (no symptoms) to 60 (worst possible symptoms). Baseline is defined as the last 28 days prior to the first day of study drug. Final Month is defined as the last 28 days prior to and including the last dose date of study drug.</description>
        <time_frame>Baseline, Days 1-28, Days 29-56, Days 57-84, Days 85-112, Days 113-140, Days 141-168, Final Month of treatment, Post-treatment (PT) Days 1-28, PT Days 29-56, PT Days 57-84, PT Days 85-112, PT Days 113-140, PT Days 141-168</time_frame>
        <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Month in Non-Bleeding Uterine Fibroids Symptom (NBUFSQ) Questionnaire</title>
          <description>The NBUFSQ (8 items) is a brief patient-reported daily diary that assesses non-bleeding symptoms experienced by women with uterine fibroids. It includes 6 items, asking women to rate their symptoms (abdominal/pelvic pain, pressure, and cramping, back pain, bloating, and urinary problems) in the past 24 hours using an 11-point numeric response scale that ranges from 0 (i.e., no symptom) to 10 (i.e., worst possible symptom) and 2 items to address urinary frequency during the daytime and at night. Data presented in the sum of scores to the 6 symptom questions, ranging from 0 (no symptoms) to 60 (worst possible symptoms). Baseline is defined as the last 28 days prior to the first day of study drug. Final Month is defined as the last 28 days prior to and including the last dose date of study drug.</description>
          <population>Modified ITT: randomized participants who received at least 1 dose of randomized, double-blind study drug in this study. Participants with an assessment at baseline and given time point.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="77"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 1-28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                    <count group_id="O7" value="71"/>
                    <count group_id="O8" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="10.11"/>
                    <measurement group_id="O2" value="-3.4" spread="8.21"/>
                    <measurement group_id="O3" value="-3.1" spread="7.88"/>
                    <measurement group_id="O4" value="-1.4" spread="6.42"/>
                    <measurement group_id="O5" value="0.4" spread="4.71"/>
                    <measurement group_id="O6" value="-2.7" spread="7.27"/>
                    <measurement group_id="O7" value="-2.1" spread="4.44"/>
                    <measurement group_id="O8" value="0.0" spread="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 29-56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="68"/>
                    <count group_id="O6" value="65"/>
                    <count group_id="O7" value="63"/>
                    <count group_id="O8" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="13.12"/>
                    <measurement group_id="O2" value="-5.8" spread="8.78"/>
                    <measurement group_id="O3" value="-4.4" spread="6.59"/>
                    <measurement group_id="O4" value="-2.9" spread="9.44"/>
                    <measurement group_id="O5" value="-0.3" spread="7.13"/>
                    <measurement group_id="O6" value="-4.2" spread="7.72"/>
                    <measurement group_id="O7" value="-2.2" spread="5.54"/>
                    <measurement group_id="O8" value="-2.3" spread="9.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 57-84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="63"/>
                    <count group_id="O7" value="56"/>
                    <count group_id="O8" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="10.94"/>
                    <measurement group_id="O2" value="-7.2" spread="11.04"/>
                    <measurement group_id="O3" value="-4.1" spread="8.4"/>
                    <measurement group_id="O4" value="-3.2" spread="11.26"/>
                    <measurement group_id="O5" value="0.1" spread="7.34"/>
                    <measurement group_id="O6" value="-4.5" spread="8.55"/>
                    <measurement group_id="O7" value="-2.2" spread="6.22"/>
                    <measurement group_id="O8" value="-3.8" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 85-112</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="55"/>
                    <count group_id="O6" value="62"/>
                    <count group_id="O7" value="55"/>
                    <count group_id="O8" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="10.74"/>
                    <measurement group_id="O2" value="-7.8" spread="11.75"/>
                    <measurement group_id="O3" value="-5.2" spread="9.05"/>
                    <measurement group_id="O4" value="-3.7" spread="10.76"/>
                    <measurement group_id="O5" value="-0.2" spread="7.47"/>
                    <measurement group_id="O6" value="-5.1" spread="9.40"/>
                    <measurement group_id="O7" value="-3.6" spread="7.35"/>
                    <measurement group_id="O8" value="-4.1" spread="8.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 113-140</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="56"/>
                    <count group_id="O6" value="57"/>
                    <count group_id="O7" value="48"/>
                    <count group_id="O8" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="13.16"/>
                    <measurement group_id="O2" value="-7.6" spread="12.03"/>
                    <measurement group_id="O3" value="-5.3" spread="9.43"/>
                    <measurement group_id="O4" value="-3.4" spread="12.1"/>
                    <measurement group_id="O5" value="0.1" spread="11.92"/>
                    <measurement group_id="O6" value="-5.5" spread="8.44"/>
                    <measurement group_id="O7" value="-4.0" spread="8.13"/>
                    <measurement group_id="O8" value="-5.3" spread="8.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 141-168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="53"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="47"/>
                    <count group_id="O8" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="14.28"/>
                    <measurement group_id="O2" value="-8.0" spread="12.65"/>
                    <measurement group_id="O3" value="-5.1" spread="9.94"/>
                    <measurement group_id="O4" value="-3.3" spread="13.01"/>
                    <measurement group_id="O5" value="-0.4" spread="10.46"/>
                    <measurement group_id="O6" value="-5.9" spread="9.45"/>
                    <measurement group_id="O7" value="-4.4" spread="8.21"/>
                    <measurement group_id="O8" value="-4.8" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="66"/>
                    <count group_id="O6" value="70"/>
                    <count group_id="O7" value="65"/>
                    <count group_id="O8" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="13.19"/>
                    <measurement group_id="O2" value="-6.7" spread="11.94"/>
                    <measurement group_id="O3" value="-4.1" spread="10.15"/>
                    <measurement group_id="O4" value="-3.5" spread="12.59"/>
                    <measurement group_id="O5" value="-0.8" spread="11.34"/>
                    <measurement group_id="O6" value="-4.0" spread="9.40"/>
                    <measurement group_id="O7" value="-3.3" spread="8.09"/>
                    <measurement group_id="O8" value="-2.3" spread="10.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT Days 1-28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="61"/>
                    <count group_id="O6" value="63"/>
                    <count group_id="O7" value="59"/>
                    <count group_id="O8" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="13.39"/>
                    <measurement group_id="O2" value="-5.2" spread="12.13"/>
                    <measurement group_id="O3" value="-3.8" spread="10.37"/>
                    <measurement group_id="O4" value="-3.0" spread="10.69"/>
                    <measurement group_id="O5" value="-0.8" spread="12.46"/>
                    <measurement group_id="O6" value="-3.8" spread="10.53"/>
                    <measurement group_id="O7" value="-2.0" spread="8.23"/>
                    <measurement group_id="O8" value="-2.3" spread="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT Days 29-56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="26"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="58"/>
                    <count group_id="O7" value="53"/>
                    <count group_id="O8" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="15.83"/>
                    <measurement group_id="O2" value="-4.1" spread="13.1"/>
                    <measurement group_id="O3" value="-1.0" spread="11.57"/>
                    <measurement group_id="O4" value="0.0" spread="9.89"/>
                    <measurement group_id="O5" value="-0.2" spread="12.49"/>
                    <measurement group_id="O6" value="-2.8" spread="11.85"/>
                    <measurement group_id="O7" value="-2.7" spread="7.58"/>
                    <measurement group_id="O8" value="-2.5" spread="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT Days 57-84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="58"/>
                    <count group_id="O6" value="55"/>
                    <count group_id="O7" value="49"/>
                    <count group_id="O8" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="17.08"/>
                    <measurement group_id="O2" value="-4.0" spread="14.11"/>
                    <measurement group_id="O3" value="-2.1" spread="10.91"/>
                    <measurement group_id="O4" value="-1.1" spread="10.50"/>
                    <measurement group_id="O5" value="-0.5" spread="13.08"/>
                    <measurement group_id="O6" value="-2.0" spread="9.79"/>
                    <measurement group_id="O7" value="-1.6" spread="8.35"/>
                    <measurement group_id="O8" value="-3.9" spread="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT Days 85-112</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="17.82"/>
                    <measurement group_id="O2" value="-6.4" spread="12.99"/>
                    <measurement group_id="O3" value="-4.8" spread="10.33"/>
                    <measurement group_id="O4" value="0.7" spread="6.59"/>
                    <measurement group_id="O5" value="-2.7" spread="7.15"/>
                    <measurement group_id="O6" value="-2.4" spread="14.37"/>
                    <measurement group_id="O7" value="-3.0" spread="7.48"/>
                    <measurement group_id="O8" value="-5.0" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT Days 113-140</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="27.8"/>
                    <measurement group_id="O2" value="-3.1" spread="2.15"/>
                    <measurement group_id="O3" value="1.3" spread="NA">only 1 participant analyzed</measurement>
                    <measurement group_id="O4" value="1.4" spread="1.75"/>
                    <measurement group_id="O5" value="-6.2" spread="1.51"/>
                    <measurement group_id="O6" value="-17.3" spread="26.2"/>
                    <measurement group_id="O7" value="-5.6" spread="6.45"/>
                    <measurement group_id="O8" value="-7.0" spread="7.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT Days 141-168</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="27.75"/>
                    <measurement group_id="O2" value="-8.0" spread="1.42"/>
                    <measurement group_id="O3" value="4.1" spread="NA">only 1 participant analyzed</measurement>
                    <measurement group_id="O4" value="-3.3" spread="NA">only 1 participant analyzed</measurement>
                    <measurement group_id="O5" value="-10.5" spread="NA">only 1 participant analyzed</measurement>
                    <measurement group_id="O6" value="-3.1" spread="NA">only 1 participant analyzed</measurement>
                    <measurement group_id="O7" value="-3.3" spread="6.42"/>
                    <measurement group_id="O8" value="-6.4" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Final Month</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.556</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from ANCOVA model with treatment as the main effect and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-1.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.58</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.65</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Final Month</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.672</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from ANCOVA model with treatment as the main effect and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.33</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final Month</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.274</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from ANCOVA model with treatment as the main effect and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>3.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.39</ci_lower_limit>
            <ci_upper_limit>8.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Final Month</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.223</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from ANCOVA model with treatment as the main effect and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-2.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.26</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Final Month</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.215</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from ANCOVA model with treatment as the main effect and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.38</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Final Month</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.392</p_value>
            <p_value_desc>P value for test of difference between each elagolix dose group and placebo at each post-baseline time point is from ANCOVA model with treatment as the main effect and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS means</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.75</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Successfully Avoided Surgical or Invasive Procedures for Uterine Fibroids</title>
        <description>The percentage of participants who successfully avoided surgical or invasive procedures for Uterine Fibroids was assessed.</description>
        <time_frame>Month 6</time_frame>
        <population>This endpoint was not completed due to lack of data collection.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Elagolix 300 mg BID</title>
            <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
            <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Elagolix 600 mg QD</title>
            <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
            <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Successfully Avoided Surgical or Invasive Procedures for Uterine Fibroids</title>
          <description>The percentage of participants who successfully avoided surgical or invasive procedures for Uterine Fibroids was assessed.</description>
          <population>This endpoint was not completed due to lack of data collection.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of study drug administration through Final Visit (Month 6 or early termination) plus 30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Placebo</title>
          <description>Placebo for elagolix BID and placebo for E2/NETA QD</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1: Elagolix 300 mg BID</title>
          <description>Elagolix 300 mg BID and placebo for E2/NETA QD</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD</title>
          <description>Elagolix 300 mg BID plus LD E2/NETA QD</description>
        </group>
        <group group_id="E4">
          <title>Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD</title>
          <description>Elagolix 300 mg BID plus SD E2/NETA QD</description>
        </group>
        <group group_id="E5">
          <title>Cohort 2: Placebo</title>
          <description>Placebo for elagolix QD and placebo for E2/NETA QD</description>
        </group>
        <group group_id="E6">
          <title>Cohort 2: Elagolix 600 mg QD</title>
          <description>Elagolix 600 mg QD and placebo for E2/NETA QD</description>
        </group>
        <group group_id="E7">
          <title>Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD</title>
          <description>Elagolix 600 mg QD plus LD E2/NETA QD</description>
        </group>
        <group group_id="E8">
          <title>Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD</title>
          <description>Elagolix 600 mg QD plus SD E2/NETA QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>MENISCUS INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>GASTRINOMA MALIGNANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>DYSMENORRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>PELVIC PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>UTERINE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="59" subjects_at_risk="77"/>
                <counts group_id="E7" subjects_affected="43" subjects_at_risk="76"/>
                <counts group_id="E8" subjects_affected="51" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="65"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="11" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E7" events="12" subjects_affected="12" subjects_at_risk="76"/>
                <counts group_id="E8" events="23" subjects_affected="20" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E8" events="7" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BACTERIAL VAGINOSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL MYCOTIC INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CHOLESTEROL INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>BONE DENSITY DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>LIPIDS INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="65"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E6" events="15" subjects_affected="13" subjects_at_risk="77"/>
                <counts group_id="E7" events="11" subjects_affected="11" subjects_at_risk="76"/>
                <counts group_id="E8" events="14" subjects_affected="14" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>DYSMENORRHOEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>PELVIC PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="32" subjects_affected="29" subjects_at_risk="65"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="64"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="39" subjects_affected="38" subjects_at_risk="77"/>
                <counts group_id="E7" events="14" subjects_affected="14" subjects_at_risk="76"/>
                <counts group_id="E8" events="11" subjects_affected="11" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

